Aggregometry and thromboelastography to identify the timing to trach a COVID-19 patient receiving both antiplatelet therapy and enoxaparin

Marco Tescione1 | Eugenio Vadala1 | Graziella Marano1 | Andrea Bruni2 |
Eugenio Garofalo2 | Ovidia Lavalle2 | Federico Longhini2 | Enzo Battaglia1 |
Nicola Polimeni1 | Demetrio Labate1 | Sarah Caracciolo3 | Francesco Giordano1 |
Massimo Caracciolo1 | Sebastiano Macheda1

Abstract
In COVID-19 patients receiving enoxaparin and antiplatelets therapy, aggregometry and thromboelastography might be considered an adjunctive tool to identify the time to perform procedures at risk of bleeding, such as tracheostomy.

KEYWORDS
aggregometry, COVID-19, SARS-CoV-2, thromboelastography, tracheostomy

1 INTRODUCTION

SARS-CoV-2 infection promotes an aggressive inflammatory response and induces a hypercoagulability status requiring enoxaparin and antiplatelet therapy. This is challenging when procedures at risk of bleeding, such as tracheostomy, are necessary. In this patient, after suspension of antiplatelet therapy, we identify the time to trach, through aggregometry and thromboelastography.

In late December 2019, clusters of patients with interstitial pneumonia of unknown cause have been reported by some local health facilities in Wuhan (China). On 7 January, the Chinese Centre for Disease Control identified a novel coronavirus (SARS-CoV-2),1 consequently declared a pandemic disease (COVID-19) by the World Health Organization on 11 March.

COVID-19 mainly affects male patients, with a median age of about 50 years; 40% of patients develop a severe acute respiratory failure (ARF), 5% requiring intensive cares.2,3 COVID-19 is also characterized by a high intensive care unit (ICU) mortality rate, with a death rate higher among older patients.4 The most common symptoms are fever followed by dry cough, shortness breath, dyspnkea, chest pain, fatigue, and myalgia.5 Less common symptoms include headache, dizziness, abdominal pain, diarrhea, sputum production, abdominal pain, nausea, and vomiting.5 Approximately 75% of patients show bilateral pneumonia.6 Different from other coronavirus infections, COVID-19 has greater preference for infecting lower respiratory tract, with severe forms of ARF complicated by shock and acute organ failures.5,6

SARS-CoV-2 is characterized by the presence of a viral protein Spike that interacts with the angiotensin-converting
enzyme-2 receptor in the host; this protein is highly expressed in lungs, intestine, oral mucosa, and liver. SARS-CoV-2 infection stirs up an aggressive inflammatory response, described as a “cytokine storm,” throughout the release of pro-inflammatory cytokines, such as the tumor necrosis factor-α, interleukin-6 (IL-6), and IL-1β. Besides causing directly organ failures, cytokine storm induces alteration of coagulation pathways, the “so called” COVID-19 coagulopathy. On the opposite, a few is known on platelet function and the role of their activation in SARS-CoV-2 infection.

In COVID-19 patients, coagulopathy may frequently complicate with deep vein thrombosis, pulmonary embolism, systemic arterial embolism, and also disseminated intravascular coagulation, which may lead to death. Furthermore, at hospital admission, COVID-19 patients commonly show increased D-dimer concentration, which is one of the predictors of mortality if markedly increased. Therefore, an accurate monitoring of coagulation and platelet aggregation may be fundamental to guide the clinician into anticoagulant and antiplatelet therapies. In particular, thromboelastography and aggregometry might be useful to help the physician to choose the right and safe time to perform invasive procedures at risk for bleeding, such as percutaneous dilatational tracheostomy. We report a mechanically ventilated COVID-19 patient, in which we interrupted clopidogrel and maintained anticoagulant therapy, and we chose the time to perform a percutaneous dilatational tracheostomy, guided by thromboelastography and aggregometry.

2 | CASE REPORT

On 23 March 2020 (Day 0), an 85-year-old Caucasian man (78 kg of actual body weight, 175 cm of height) was admitted to the Emergency Department for progressive respiratory symptoms and fever (38.5°C). In the 12 days preceding hospital admission, the patient reported fever and sore throat. Due to the medical history, a nasal and pharyngeal swab was performed and SARS-CoV-2 infection confirmed. Therefore, further investigations (such as bronchoalveolar lavage and/or serological tests) were not considered necessary. Comorbidities were arterial hypertension treated with amlodipine and untreated prostatic hypertrophy.

At admission, he was spontaneously breathing in room air, with a respiratory rate >25 breaths/min; the oxygen arterial partial pressure (PaO2) to inspired fraction (FiO2) ratio (PaO2/FiO2) was 290 mm Hg, as assessed through arterial blood gases (ABGs) analysis. Hemodynamic was stable (ie, a mean arterial blood pressure (MAP) >65 mm Hg), while sequential organ failure assessment (SOFA) score was 4.

At admission, a general inflammatory status with alterations of part of coagulation tests was observed, in the absence of kidney, liver, and heart injuries. The patient was therefore admitted to a COVID-19 ward and treated with antibiotic at broad spectrum (ceftriaxone 2 g once daily till Day 8), hydroxychloroquine, and oxygen through a Venturi mask with a FiO2 at 30%.

On Day 3, CT scan showed bilateral, patchy alveolar opacities progressing to diffuse consolidations, with a “white lung” appearance and widespread ground-glass opacities and moderate bilateral pleural effusions. On Day 4, patient’s condition progressively worsened and continuous positive airway pressure (CPAP) through helmet was attempted. Azithromycin 500 mg twice daily was also introduced; furthermore, according to an ongoing trial, tocilizumab 8 mg/kg was administered intravenously and repeated after 12 hours.

Antibiotic therapy was then modulated according to bacteria isolation. On Day 15, due to isolation of Acinetobacter baumannii in the sputum, gentamicin (480 mg/daily) and aerosolized colistin (3 billion-unit trice/daily) were initiated.

At Day 23, clinical condition suddenly precipitated; PaO2/FiO2 was 103 mm Hg, deeming necessary ICU admission and CPAP resuming. Due to the lack of gas exchange improvement and onset of kidney and heart failure, the patient was intubated and mechanically ventilated with a protective ventilation strategy. Prone position was applied for prolonged (>16 hours) sessions. Norepinephrine from 0.1 to 0.6 mcg/kg/min was started and titrated according to the hemodynamics, in order to target a MAP >65 mmHg. Table 1 reports the blood test at ICU admission and along the first month of ICU stay. Due to the hypercoagulability related to COVID-19, Enoxaparin 8000 UI twice daily was administered subcutaneously; in addition, we also administered clopidogrel 75 mg once daily.

Since the clinical conditions barely improved and extubation was not possible due to the permanence of poor gas exchange, on Day 37 we decided to tracheostomy the patient, with a percutaneous single-stage dilatational technique (Ultraperc®; Portex; Smiths Medical Inc). Of note, this clinical decision kept with the more recently published guidance on tracheostomy in COVID-19 patients. However, due to the anticoagulant and antiplatelet therapies, we decided to stop the administration of clopidogrel, while keeping enoxaparin, and to monitor the coagulation status with thromboelastography (TEG®6S; Haemonetics) and platelet function (PlateletMapping® ADP, Haemonetics).

As shown in Table 2, measurements were done at Day 37 (when tracheostomy was decided and clopidogrel stopped), Day 38, 40 (day of tracheostomy), and 42 (24 hours after clopidogrel resumption). In addition, we also investigated the following: (a) the coagulation with laboratory tests, that is, prothrombin time (PT), partial thromboplastin time (PTT),
activated partial thromboplastin time (aPTT), and D-dimer; and (b) the IL-6 blood concentrations.

During the whole hospitalization, the patient underwent periodical SARS-CoV-2 swab surveillance tests. Complete viral shedding with the first pharyngeal swab negative for SARS-CoV-2 was detected on Day 50. Patient was weaned-off invasive mechanical ventilation on Day 48,16,17 and he was discharged from ICU on Day 56.

3 | DISCUSSION

We report a case of COVID-19 patient receiving both anticoagulant and antiplatelet therapies, in which the choice of the timing for tracheostomy was also guided by aggregometry and thromboelastography.

SARS-CoV-2 infection has been initially reported in the literature as a viral and interstitial pneumonia1; advances of research and knowledge on pathophysiology suggest that SARS-COV-2 infection promotes a cytokine storm and a COVID-19–related hypercoagulability condition.3,8,9 Indeed, COVID-19 patients are characterized by a state of hypercoagulability, as compared to healthy adults.18,19 In particular, as compared to controls, $R$ and $K$ values have been reported to be shorter in 50% and 83% COVID-19 patients, respectively. Moreover, K and MA angle were also higher in 72% and 83% in COVID-19 population, as compared to controls. Finally, Lys-30 was lower than reference population in all patients affected by SARS-CoV-2 infection.18 Spiezia et al reported that, compared to controls, COVID-19 patients are characterized by higher fibrinogen and D-dimer plasma levels, with markedly hypercoagulable ROTEM profiles characterized by significantly shorter clot formation time in the evaluations of both intrinsic (INTEM) and extrinsic (EXTEM) coagulation pathways, and by a higher maximum clot firmness in INTEM, EXTEM, and in the evaluation of fibrinogen contribution to blood clot (FIBTEM).19 In fact, thromboembolic complications represent a part of the clinical picture of COVID-19 and can be already present at the time of hospital admission.20 For these reasons, firstly several treatments with anti-inflammatory drugs or monoclonal antibodies have been attempted to modulate the cytokine storm; however, the awareness of the hyper-coagulability has pushed physician to start also anticoagulant therapies with low-molecular-weight heparin at high dosage and, sometimes, antiplatelet therapy.21-23

| TABLE 1 | Blood test during the first month of ICU admission |
|----------|--------------------------------------------------|
|          | Normal range | ICU admission (Day 23) | Day 30 | Day 35 | Day 37 | Day 42 | Day 51 |
| WBC ($10^9$/L) | 4.5-11 | 4.42 | 5.11 | 13.86 | 13.22 | 10.66 | 12.70 |
| RBC ($10^5$/mm$^3$) | 4.7-6.1 | 4.37 | 3.90 | 3.28 | 3.68 | 3.03 | 3.01 |
| Platelet ($10^3$/mm$^3$) | 150-450 | 135 | 113 | 322 | 438 | 337 | 204 |
| Creatinine clearance (mL/min) | 88-128 | 98.8 | 78.3 | 68.3 | 80.2 | 38.7 | 86.1 |
| AST (UI/L) | 8-40 | 32 | 19 | 24 | 18 | 19 | 14 |
| ALT (UI/L) | 8-40 | 57 | 21 | 25 | 13 | 33 | 12 |
| Lactate dehydrogenase (UI/L) | 140-280 | 301 | 225 | 265 | 285 | 363 | 178 |
| IL-6 (pg/mL) | 0-16.4 | 4226 | 463 | 90.6 | 752 | 90.6 | 100 |
| Procalcitonin (ng/mL) | <0.2 | 0.08 | 0.22 | 0.28 | 0.26 | 0.83 | 0.52 |
| C-reactive protein (mg/dL) | <10 | 31.4 | 10.50 | 77.8 | 123 | 79.1 | 76.8 |
| Glycemia (mg/dL) | 70-130 | 115 | 117 | 187 | 126 | 163 | 162 |
| Troponin (ng/L) | <0.04 | <0.012 | 0.081 | 0.073 | 0.029 | 0.068 | 0.081 |
| Fibrinogen (mg/mL) | 200-400 | 202 | 270 | 400 | 619 | 432 | 327 |
| D-dimer (ng/mL) | 0-50 | 386 | 280 | 328 | 542 | 469 | 457 |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ICU, intensive care unit; IL-6, interleukin; RBC, red blood cell; WBC, white blood cell.
Based on this knowledge, we adopted the clinical choice to administer both anticoagulant and antiplatelet therapies to our patients in ICU. It should be noted that among severe COVID-19 patients with elevated D-dimer levels, a high incidence of thromboembolic complications, despite standard low-dose prophylaxis, has been reported. For these reasons, an intermediate-intensity or full-dose anticoagulation has been routinely used, as opposed to standard low-intensity prophylaxis. However, these therapies could have limited our treatment choice, in particular for most invasive procedures such as percutaneous tracheostomy at the bedside, due to the increased risk of bleeding. Indeed, bleeding is the most frequent perioperative and postprocedural complication after percutaneous dilatational tracheostomy, with a reported incidence of around 5%.

It should be also criticized that we performed a late tracheostomy, instead an early strategy. In the past, a great challenge has been to assess the effectiveness and safety of early vs late tracheostomy in critically ill adults with different clinical conditions, with respect to their clinical outcomes. Early tracheostomy is defined as a procedure performed within the first 10 days from tracheal intubation, while late tracheostomy if occurring later than 10 days. Results from the literature are quite contradictory. A systematic review and meta-analysis reported a moderate quality of evidence for a lower mortality rate at the longest follow-up time in the group receiving early tracheostomy, than late tracheostomy (47.1% vs 53.2%, respectively), with a statistically significant risk ratio of 0.83 (95% confidence interval 0.70–0.98; \( P = .03 \)). However, the procedure of tracheostomy should not follow strict rules regarding time, but should be tailored to the individual patient. Furthermore, tracheostomy is an aerosol-generating procedure. So, healthcare workers are at risk of infection during insertion and subsequent care, even when appropriate personal protective equipment is used. While on the one hand, delaying tracheostomy might reduce risks for staff and allow disease resolution with the possibility of weaning from mechanical ventilation and extubation, on the other hand, it prolongs duration of translaryngeal intubation, sedation, mechanical ventilation, and ICU stay. After contemplating all these considerations, we decided for a late tracheostomy.

When we decided to tracheostomize our patient, we stopped antiplatelet therapy and kept the anticoagulant therapy ongoing, although some papers suggest that antiplatelet therapy may not be interrupted and mild coagulative disorders not corrected before percutaneous dilatational tracheostomy. However, after performing advanced coagulation and aggregation tests, we obtained an objective evaluation of thromboelastography and aggregometry that lead us to act in this way. In fact, at the time the patient was admitted (end of March 2020), a few was known on the coagulative disorder correlated with SARS-CoV-2 infection. Therefore, the choice of the right time to perform tracheostomy was cautionary dictated by the daily coagulation blood test and platelet counts, in addition to thromboelastography and aggregometry. In fact, as we have shown in our case, we stopped the administration of clopidogrel, and after 3 days, the MA and the aggregation (%) fall within the normal range and percutaneous dilatational tracheostomy was safely performed at the bedside without bleeding complications. Therefore, our strategy has been revealed to be successful for our scope. Furthermore, we decided to restart antiplatelet therapy 24 hours after tracheostomy, in order to reduce as much as possible, the risk of platelet aggregation and thromboembolic events.

Although this was a successful strategy in the management of our patient, this remains a simple case report. Therefore, it should be considered as simple report, and not to be taken as a general practice to be applied in all patients. Further studies, with a proper design, are therefore required, to address whether this strategy is superior to others.

In conclusion, COVID-19 is a disease with a major coagulative disorder that requires an important anticoagulant and antiplatelet therapy. The performance of a percutaneous dilatational tracheostomy might be complicated by the required therapy. In this COVID-19 case, we decided to tracheostomy the patient guided by thromboelastography and aggregometry, after the interruption of antiplatelet drugs. This clinical choice, done in the beginning of the SARS-CoV-2 epidemic in our region, was successful and might be a strategy to be considered in complicated patients.

**Table 2: Coagulation, thromboelastography, and platelet function test**

|                      | Day 37 | Day 38 | Day 40 | Day 42 |
|----------------------|--------|--------|--------|--------|
| Coagulation test     |        |        |        |        |
| PT (seconds)         | 13.00  | 13.20  | 12.80  | 12.80  |
| PTT (seconds)        | 36.70  | 31.40  | 34.10  | 34.20  |
| aPTT                 | 1.15   | 0.98   | 1.07   | 1.07   |
| D-dimer (mg/mL)      | 328    | 516    | 781    | 585    |
| Thromboelastography (TEG®6S) |        |        |        |        |
| R (minutes)          | 8.5    | 8.9    | 8.5    | 8.4    |
| K (minutes)          | 1.2    | 1.0    | 1.1    | 1.0    |
| Angle (°)            | 75.3   | 76.9   | 76.4   | 76.3   |
| MA (mm)              | 66     | 68.1   | 68.6   | 66.3   |
| LY30 (%)             | 0.00   | 0.00   | 0.00   | 0.00   |
| TEG ACT              | 78     | 78.5   | 82     | 81.2   |
| Platelet function (PlateletMapping® ADP) |        |        |        |        |
| MA ADP (mm)          | 25.1   | 28     | 52.6   | 52.8   |
| Aggregation (%)      | 10.9   | 9.7    | 83.5   | 70.6   |
ACKNOWLEDGMENTS

None.

Consent for publication: Signed consent for publication was obtained.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

MT, EV, GM, EB, NP, DL, SC, FG, MC and SM: made substantial contributions to patient’s care; MT, AB, EG, OL, and FL: took part in the data acquisition, analysis, and interpretation, and they were involved in drafting the manuscript. FL, EV, GM, EB, NP, DL, SC, FG, MC, and SM: revised the manuscript for important intellectual content. All authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

ETHICAL APPROVAL AND CONSENT TO PARTICIPATE

Patient signed the informed consent modules and accepted the publication of clinical data for research and scientific purposes.

DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this paper.

ORCID

Marco Tescione https://orcid.org/0000-0002-0053-6935
Federico Longhini https://orcid.org/0000-0002-6970-7202

REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
2. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. JAMA Intern Med. 2020;180:934.
3. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 in China, 2019. Lancet. 2020;395(10223):1708-1720.
4. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323:1574.
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
7. Ashour HM, Elkhadib WF, Rahman MM, Elshabrawy HA. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens. 2020;9(3):186.
8. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.
9. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
10. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020;48:1358-1364.
11. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
12. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324-1329.
13. Longhini F, Bruni A, Garofalo E, et al. Helmet continuous positive airway pressure and prone positioning: a proposal for an early management of COVID-19 patients. Pulmonology. 2020;26:186-191.
14. Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-2168.
15. McGrath BA, Brenner MJ, Warrillow SJ, et al. Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. Lancet Respir Med. 2020;8(7):717-725.
16. Longhini F, Pisani L, Lungu R, et al. High-flow oxygen therapy after noninvasive ventilation interruption in patients recovering from hypercapnic acute respiratory failure: a physiological cross-over trial. Crit Care Med. 2019;47(6):e506-e511.
17. Longhini F, Maugeri J, Andreoni C, et al. Electrical impedance tomography during spontaneous breathing trials and after extubation in critically ill patients at high risk for extubation failure: a multicenter observational study. Ann Intensive Care. 2019;9(1):88.
18. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18:1738-1742.
19. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998-1000.
20. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.
21. McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2(7):e437-e445.
22. Lazzaroni MG, Piantoni S, Masneri S, et al. Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system. Blood Rev. 2020;1:100745. [Online ahead of print]
vascular anatomy of the anterior neck. A review based on 497 cases. *Int J Oral Maxillofac Surg.* 2000;29(3):217-222.

26. Andriolo BN, Andriolo RB, Saconato H, Atallah AN, Valente O. Early versus late tracheostomy for critically ill patients. *Cochrane Database Syst Rev.* 2015;1:CD007271.

27. Deppe AC, Kuhn E, Scherner M, et al. Coagulation disorders do not increase the risk for bleeding during percutaneous dilatational tracheotomy. *Thorac Cardiovasc Surg.* 2013;61(3):234-239.

28. Veelo DP, Vlaar AP, Dongelmans DA, et al. Correction of subclinical coagulation disorders before percutaneous dilatational tracheotomy. *Blood Transfus.* 2012;10(2):213-220.

How to cite this article: Tescione M, Vadala E, Marano G, et al. Aggregometry and thromboelastography to identify the timing to trach a COVID-19 patient receiving both antiplatelet therapy and enoxaparin. *Clin Case Rep.* 2021;9:1049–1054. 
https://doi.org/10.1002/ccr3.3442